| PE22.01 | Directly Observed Therapy (DOT) can be Implemented Successfully in Research Settings to Evaluate PrEP PK among Pregnant and Postpartum Adolescents and Young Women in Africa | E-poster | Novel vaccine and other prevention approaches |
| PU21.01 | Willingness of adolescent girls and young women in Kampala, Uganda to participate in future efficacyttrials of novel biomedical HIV prevention interventions: the anti-retroviral implant | Publication Only | Novel vaccine and other prevention approaches |
| PU21.02 | Comparison of HIV incidence in simulated vaccine efficacy trials and observational cohorts using propensity scores in key populations in Uganda | Publication Only | Novel vaccine and other prevention approaches |
| PU21.03 | Co-display of hyperstabilized HIV-1 envelope glycoprotein trimers on two-component protein nanoparticles | Publication Only | Novel vaccine and other prevention approaches |
| PU21.03 | Assessment of crosslinker suitability for fusion peptide conjugates as priming immunogens for an HIV-1 vaccine | Publication Only | Novel vaccine and other prevention approaches |
| PU21.06 | DNA vs ChAd-vectored vaccines as priming vaccines in heterologous prime-boost regimens to increase HTI immunogenicity in mice | Publication Only | Novel vaccine and other prevention approaches |
| PU21.08 | Distinct classes of HIV-1 cross-clade neutralizing antibodies targeting fusion peptide elicited in mice by diverse immunization regimens | Publication Only | Novel vaccine and other prevention approaches |
| OA04.03 | Distribution of long-acting (LA) cabotegravir (CAB) in plasma, mucosal tissues, and associated fluids after a single ultrasound-guided intramuscular (IM) injection in healthy adult participants | Oral Abstract Session | Pharmacology/PK and PD studies |
| OA16.05 | A randomized, double blind, placebo-controlled, phase 1 safety and pharmacokinetic study of dapivirine gel (0.05%) administered rectally to HIV-1 seronegative adults (MTN-026) | Oral Abstract Session | Pharmacology/PK and PD studies |
| OA19.05LB | Pharmacokinetic and pharmacodynamic study of tenofovir and tenofovir alafenamide for PrEP in foreskin tissue | Oral Abstract Session | Pharmacology/PK and PD studies |